

1 **The persistent underrepresentation of patients with chronic kidney disease in**  
2 **cardiovascular trials: a systematic review and evidence map of exclusion and**  
3 **outcomes**

4  
5 Julia M.T. Colombijn<sup>1,2</sup>, Demy L. Idema<sup>3</sup>, Sanne van Beem<sup>1</sup>, Anna Marthe Blokland<sup>1</sup>, Kim van  
6 der Braak<sup>3</sup>, M. Louis Handoko<sup>4,5</sup>, Linde F. Huis in 't Veld<sup>3</sup>, Tabea Kaul<sup>2</sup>, Nurda Kolagasigil-  
7 Akdemir<sup>1</sup>, Mike P.T. Kusters<sup>3</sup>, Sabine C.A. Meijvis<sup>1</sup>, Ilse J. Oosting<sup>1,2</sup>, Rene Spijker<sup>3,6</sup>, Michiel  
8 L. Bots<sup>2</sup>; Lotty Hooft<sup>3</sup>, Marianne C. Verhaar<sup>1</sup>, Robin W.M. Vernooij<sup>1,2</sup>

9  
10 1 Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, the  
11 Netherlands

12 2 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,  
13 Utrecht University, Utrecht, the Netherlands

14 3 Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University  
15 Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

16 4 Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam  
17 Cardiovascular Sciences, Amsterdam, the Netherlands

18 5 Amsterdam Cardiovascular Sciences (Heart Failure & Arrhythmias), Amsterdam, The  
19 Netherlands

20 6 Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health,  
21 Amsterdam, Netherlands

22  
23 **Corresponding author:** Dr. Robin W.M. Vernooij

24 Visiting address: Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands

25 Tel: +31 (0)88 75 555 55

26 Email address: [r.w.m.vernooij-2@umcutrecht.nl](mailto:r.w.m.vernooij-2@umcutrecht.nl)

27 **Sponsor:** Dutch Heart Foundation, 2020B008 RECONNECT

28 Number of tables: 1

29 Number of figures: 5

30 Abstract word count: 320

31 Word count: 3451

32 Keywords: Cardiovascular disease, cardiovascular risk management, chronic kidney

33 disease, kidney failure, systematic review

34

35 **Abstract**

36 Background: Patients with chronic kidney disease (CKD) are at high risk for cardiovascular  
37 disease, but their systematic underrepresentation in cardiovascular randomised controlled  
38 trials (RCTs) limits appropriate evidence to guide cardiovascular risk management (CVRM).  
39 This systematic review aims to evaluate trends in the underrepresentation of patients with  
40 CKD in cardiovascular RCTs in the past 20 years and highlight evidence gaps for CVRM  
41 medications in this population.

42

43 Methods: A systematic search was conducted in ClinicalTrials.gov from its inception in 2000  
44 until October 2021, targeting RCTs evaluating the efficacy of CVRM medications on  
45 mortality, cardiovascular disease, and kidney failure in adults with cardiovascular disease or  
46 one or more cardiovascular risk factors. Two reviewers independently screened references  
47 and extracted data. Outcomes were the exclusion rate of patients with CKD over time and an  
48 evidence map of studies reporting results for this population.

49

50 Results: In total, 1194 RCTs involving 2,207,677 participants were included. Since 2000, the  
51 percentage of cardiovascular RCTs that exclude patients with CKD has increased from 66%  
52 to 79% (74% overall, 884 RCTs). In 73% of RCTs, more patients were excluded than  
53 anticipated on safety grounds (63% without dose adjustment necessary and 79% of RCTs  
54 with dose adjustment necessary). In total, 158 RCTs (13%) reported results patients with  
55 CKD separately (e.g. in subgroup analyses). Significant evidence gaps exist for most CVRM  
56 interventions for patients with CKD, particularly for those with CKD stage 4-5. For patients  
57 with an eGFR <30 ml/min/1.73m<sup>2</sup>, 23 RCTs reported results, for dialysis patients 15 RCTs,  
58 and for kidney transplant patients only 1 RCT.

59

60 Conclusion: The underrepresentation of patients with CKD in cardiovascular RCTs has not  
61 improved in the past two decades and three-quarters of RCTs excluded more patients than  
62 expected on safety grounds. A lack of RCTs that report results for patients with CKD has

63 resulted in significant evidence gaps for most CVRM medications in all subgroups of patients

64 with CKD, in particular for those with CKD stage 4-5.

65

66 Primary funding source: Dutch Heart Foundation, 2020B008 RECONNECT

67

68 Registration: PROSPERO (CRD42022296746)

69

70 **Introduction**

71

72 Chronic kidney disease (CKD) affects almost 700 million patients worldwide and is the cause  
73 of 1.9 million cardiovascular deaths annually (1, 2). Over 60% of patients with CKD has a  
74 history of cardiovascular disease and this is also the main cause of death in this population  
75 (3, 4). Almost all patients with CKD have a much higher risk for CVD than for kidney failure  
76 (5, 6). This elevated CVD risk is already observed for patients with an estimated glomerular  
77 filtration rate (eGFR)  $<75$  ml/min/1.73m<sup>2</sup> and increases as CKD progresses, independently of  
78 other risk factors like hypertension and diabetes (3, 7).

79

80 The high cardiovascular risk in patients with CKD underscores the importance of effective  
81 strategies for cardiovascular risk management (CVRM) for patients with CKD. Nevertheless,  
82 even though over 90% of patients with CKD are being prescribed CVRM medications,  
83 evidence on the safety and efficacy of these medications in patients with CKD is limited (8,  
84 9). Historically, patients with CKD largely have been underrepresented in cardiovascular  
85 randomised controlled trials (RCTs). They are frequently excluded due to concerns about the  
86 safety and efficacy of interventions. Even the RCTs without explicit CKD exclusion criteria  
87 often do not include these patients nor assess treatment effects for them (10-13).

88

89 A lack of information about the efficacy of CVRM medications in people with CKD  
90 undermines effective CVRM treatment. Efficacy estimates about CVRM medications from  
91 RCTs excluding patients with CKD cannot be extrapolated carelessly since the increased  
92 CVD risk in patients with CKD and altered pathophysiology of CVD can modify the efficacy of  
93 treatments (14). As CKD progresses to kidney failure, patients' CVD burden shifts from  
94 atherosclerotic CVD to medial arterial calcification, cardiac arrhythmias, left-ventricular  
95 hypertrophy, and sudden cardiac death (14). A higher cardiovascular risk could enhance the  
96 efficacy of CVRM treatments for patients with CKD as a greater absolute risk reduction can  
97 be achieved. However, a reduced life expectancy and the induction of additional pathways in

98 CVD pathophysiology which are not inhibited by traditional CVRM medications could offset  
99 these benefits and render treatment futile (15).

100

101 Several systematic reviews, which included RCTs published up to 2014, have reported on  
102 the underrepresentation of patients with CKD in cardiovascular RCTs (10-13). However, it is  
103 unclear whether the representation of patients with CKD in cardiovascular RCTs has  
104 improved over the past years and whether this population has been included in RCTs  
105 evaluating the efficacy of (relatively) new treatments, such as sodium glucose-cotransporter-  
106 2 inhibitors (SGLT2-inhibitors) and direct oral anticoagulants (DOACs). Furthermore, the  
107 systematic exclusion of patients with CKD makes it uncertain for which CVRM medications  
108 evidence is available on the efficacy and safety specifically for people with CKD. An overview  
109 of the RCTs evaluating the efficacy of CVRM medications for (different subgroups of)  
110 patients with CKD is currently lacking. Therefore, the aim of this systematic review was to  
111 evaluate trends in the underrepresentation of patients with CKD from cardiovascular RCTs in  
112 the past 20 years, and to create an overview of the available evidence, highlighting evidence  
113 gaps for CVRM medications for patients with CKD.

## 114 **Methods**

115 This systematic review has been reported according to the Preferred Reporting Items for  
116 Systematic Reviews and Meta-Analyses (PRISMA) and registered prospectively in  
117 PROSPERO (CRD42022296746) (16). The full protocol has been published previously (17).

118

### 119 *Data sources and searches*

120 In brief, ClinicalTrials.gov was searched through the Cochrane Central Register of Controlled  
121 Trials from inception (February 2000) until October 2021 with a combination of keywords for  
122 CVD, cardiovascular risk factors and the included interventions to identify planned, ongoing,  
123 terminated, and completed RCTs. Next, the full-text publications were retrieved up to May  
124 2023 from ClinicalTrials.gov. If no full texts were listed in ClinicalTrials.gov, MEDLINE,  
125 Embase, and Google Scholar were searched additionally to retrieve the full texts. Records of  
126 which no publications could be found were excluded. Landmark RCTs not identified in our  
127 search were added manually.

128

### 129 *Study selection*

130 Two reviewers screened clinical trial records and publications independently based on the  
131 eligibility criteria. Disagreements were resolved by discussion.

132

133 Eligible RCTs were those evaluating the effect of antiplatelets, anticoagulants, blood  
134 pressure-lowering drugs, glucose-lowering drugs, or cholesterol-lowering drugs  
135 recommended by the European Society of Cardiology, the American Heart Association, the  
136 American Stroke Association, the American College of Cardiology, and the American  
137 Diabetes Association for the prevention of CVD (18-39) on all-cause or cardiovascular  
138 mortality, cardiovascular disease (as composite endpoint and individual events), peripheral  
139 arterial disease, or kidney failure, in adults with a history of CVD or one or more CVD risk  
140 factors. Interventions must be compared against placebo, usual care, another therapy, or a  
141 different treatment dosage or duration.

142

143 *Data extraction and quality assessment*

144 Data extraction was performed by one reviewer with a standardised extraction form and

145 verified by a second reviewer. A list of extracted variables is described in the protocol (17).

146 Risk of bias was not assessed since bias in study design is unlikely to affect whether patients

147 with CKD are excluded from RCTs or whether authors report results for them (as subgroup

148 analysis or by restriction of the study population).

149

150 *Data synthesis and analysis*

151 Outcomes of interest were the frequency of exclusion of patients with CKD and the reporting

152 of results for patients with CKD (through subgroup analyses or restriction of the study

153 population). Exclusion of patients with CKD was defined as the exclusion of patients on

154 kidney-related eligibility criteria. If RCTs did not specify kidney-related eligibility criteria, we

155 presumed these patients were not excluded.

156

157 Categorical variables were described as frequency (percentage) and continuous variables as

158 mean (standard deviation) if they followed a normal distribution and otherwise as median

159 [interquartile range]. The frequency of exclusion of patients with CKD was evaluated for

160 different time periods, medications, and dosing recommendations for patients with CKD.

161 Dosing recommendations were categorised based on the Renal Drug Handbook as no dose

162 adjustment necessary, dose adjustment in CKD stage 3, or 4-5, and contra-indicated in CKD

163 stage 4, or 5 (40).



## 164 **Results**

### 165 **Study selection, and characteristics of studies and participants**

166 Overall, 13,017 RCTs were identified in the search of which 8,780 were excluded on  
167 ClinicalTrials.gov record. Of 1419 RCTs, no full-text was retrieved. Of the remaining 2818  
168 records screened on full text, 1,194 RCTs involving 2,207,677 participants were included  
169 (Supplementary Figure 1). Main reasons for exclusion were no outcomes of interest (n=884),  
170 no interventions of interest (n=304), and insufficient sample size (n=77). Included RCTs had  
171 a median follow-up of 24 months [IQR 12.0 – 39.6] and 82 (7%) had published a protocol  
172 only. Glucose-lowering drugs were evaluated in 552 RCTs (46%), antiplatelets and  
173 anticoagulants in 229 RCTs (19%), blood pressure-lowering drugs in 221 RCTs (19%), and a  
174 combination of these interventions in 30 RCTs (3%) (Table 1).

175

176 Participants had a mean age of 63±6 years and the mean percentage of women was 36±12.  
177 The mean eGFR was 73±13 ml/min/1.73m<sup>2</sup> and the median serum creatinine level was 1.00  
178 [0.96-1.04] mg/dl but these variables were reported in only 295 (25%) and 154 (13%) RCTs,  
179 respectively. Patients receiving dialysis were included in 17 RCTs (1%) and patients with a  
180 kidney transplant in 1 (<1%) RCT. An overview of included RCTs and their characteristics is  
181 listed in Supplemental Table 1.

182

### 183 **Trends in the underrepresentation of patients with CKD**

184 Since 2000, the percentage of RCTs that excluded (subgroups of) patients with CKD has  
185 increased from 66 to 79% (74% overall, 884 RCTs; Figure 1a). Patients with CKD stage 1-3  
186 (i.e., eGFR >30 ml/min/1.73m<sup>2</sup>, serum creatinine <2 mg/dL or a history of CKD) were  
187 excluded in 458 RCTs (38% of all included RCTs and 52% of RCTs which excluded patients  
188 with CKD) (Figure 1a). In the past 20 years, patients with CKD stage 4-5 have been excluded  
189 from cardiovascular RCTs more frequently while the exclusion of patients with CKD stage 1-  
190 3 has remained stable (Figure 1a). The proportion of RCTs where dose adjustment based on

191 kidney function was required or where medication was contra-indicated on kidney function  
192 remained consistent across this different time period (Figure 2b, Supplemental Figure 2). The  
193 kidney exclusion criteria applied were heterogeneous, but generally based on eGFR (n=442,  
194 50%) or serum creatinine (n=324, 37%) (Figure 1c). The exclusion of patients with CKD for  
195 individual drug groups is illustrated in Figure 1b.

196

197 In 73% of RCTs, more patients with CKD were excluded than expected on safety grounds.  
198 Patients with CKD were excluded in 63% of RCTs where no dose adjustment for the  
199 interventions on kidney function was required (306/488). The rate of exclusion of patients  
200 with CKD was over 80% in RCTs where the dose-adjustments based on kidney function were  
201 necessary or interventions were contra-indicated based on kidney function. However, 79% of  
202 these RCTs (558/706 RCTs) also excluded more patients with CKD than necessary on  
203 safety grounds (Figure 2a).

204

#### 205 **Evidence (gaps) for CVRM medications in patients with CKD**

206 In total 158 RCTs (13%) reported results for patients with CKD. Of these RCTs, 34 (3%) only  
207 included patients with CKD (4 cholesterol-lowering drugs, 13 blood-pressure lowering drugs,  
208 15 glucose-lowering drugs, and 2 antithrombotic drugs). The percentage of RCTs that  
209 reported results for patients with CKD has not improved in the past 20 years (Figure 3b)  
210 Analyses for patients with CKD were predominantly performed for composite cardiovascular  
211 endpoints (112 RCTs, 66%) in heterogeneous strata (Figure 3a, 4, and 5). Few RCTs  
212 conducted analyses for individual cardiovascular endpoints, particularly for heart failure,  
213 peripheral arterial disease, and kidney failure (Figure 3a, Supplemental tables 3-9). RCTs  
214 that conducted subgroup analyses for patients with CKD had a mean baseline eGFR of  
215  $71 \pm 12$  ml/min/1.73m<sup>2</sup>, although this parameter was reported in only 40% of the RCTs.

216

217 We identified significant gaps in evidence for CVRM medications for all patients with CKD.

218 Evidence gaps were most notable for patients with CKD stage 4-5 for whom 39 RCTs

219 reported results (23 for eGFR <30 ml/min/1.73m<sup>2</sup>, 10895 participants; 15 for dialysis 9516  
220 participants, 1 for kidney transplant recipients; 2102 participants. Figures 4 and 5). An  
221 overview of analyses for endpoints other than major adverse cardiovascular events (MACE)  
222 is added in the supplementary materials (Supplementary Figures 3-9).

223

#### 224 *Blood pressure-lowering drugs*

225 Most RCTs evaluating blood pressure-lowering drugs for the prevention of major adverse  
226 cardiovascular events (MACE) for patients with CKD studied angiotensin-converting enzyme-  
227 inhibitors (ace-inhibitors, angiotensin receptor blockers (ARBs) and mineralocorticoid  
228 receptor blockers (MRAs) (Figures 4 and 5). For patients with an eGFR <60 ml/min/1.73m<sup>2</sup>,  
229 each antihypertensive was evaluated in at least 1 RCT except for alpha-blockers. ARBs, beta  
230 blockers and MRAs were evaluated for both patients with an eGFR <30 ml/min/1.73m<sup>2</sup> and  
231 patients receiving dialysis. Ace-inhibitors and calcium channel blockers were also evaluated  
232 for patients receiving dialysis and thiazides for patients with an eGFR <30 ml/min/1.73m<sup>2</sup>.  
233 Other antihypertensives were not evaluated in these populations. None of the RCTs  
234 evaluated the efficacy of antihypertensives for patients with a kidney transplant (Figures 4  
235 and 5).

236

#### 237 *Cholesterol-lowering drugs*

238 The efficacy of cholesterol-lowering drugs in patients with CKD on MACE was evaluated  
239 almost exclusively for statins but barely for other cholesterol-lowering drugs (Figures 3 and  
240 4). Statins were evaluated for patients with an eGFR <60 ml/min/1.73m<sup>2</sup> as monotherapy or  
241 in combination with ezetimibe. PCSK-9 (proprotein convertase subtilisin/kexin type 9)  
242 inhibitors, niacin, and icosapent ethyl were also evaluated for this population but not for  
243 patients with CKD stage 4-5. For patients with an eGFR <30 ml/min/1.73m<sup>2</sup>, the combination  
244 of statins with ezetimibe was the only therapy evaluated. For patients receiving dialysis,  
245 statins were evaluated as monotherapy and combination with ezetimibe. For patients with a

246 kidney transplant, statin monotherapy was evaluated but none of the other drugs (Figures 4  
247 and 5).

248

#### 249 *Antiplatelets and anticoagulants*

250 Of all CVRM medications, antiplatelets and anticoagulants were studied most frequently for  
251 patients with CKD (Figures 3 and 4). At least 10 RCTs evaluated the efficacy of single  
252 antiplatelet therapy, double antiplatelet therapy (SAPT and DAPT, respectively), and DOACs  
253 for patients with CKD. However, these analyses were largely restricted to patients with an  
254 eGFR <60 ml/min/1.73m<sup>2</sup> (Figures 3 and 4). The efficacy of triple antiplatelet therapy or  
255 combinations of DAPT or SAPT with vitamin K antagonist (VKAs) or DOACs was evaluated  
256 in a handful of RCTs and only one of these RCTs evaluated the efficacy of these  
257 interventions in patients with an eGFR <60 ml/min/1.73m<sup>2</sup>. For patients with an eGFR <30  
258 ml/min/1.73m<sup>2</sup>, the efficacy of SAPT, DAPT, DOACs, and a combination of DOACs with  
259 SAPT was evaluated. For patients receiving dialysis, evidence was limited to the comparison  
260 of DOACs with VKAs and the efficacy of antiplatelets was not evaluated at all. None of the  
261 RCTs evaluated the efficacy of antiplatelets and anticoagulants for patients with a kidney  
262 transplant (Figures 4 and 5).

263

#### 264 *Glucose-lowering drugs*

265 The efficacy of newer glucose-lowering drugs (SGLT-1 inhibitors and GLP-1 receptor  
266 agonists) on MACE for patients with CKD was evaluated in multiple RCTs. However, hardly  
267 any evidence was available for older glucose-lowering drugs (metformin, sulphonylureas,  
268 and insulin; Figures 3 and 4). Similarly to antiplatelets and anticoagulants, evidence was  
269 mainly restricted to patients with an eGFR <60 ml/min/1.73m<sup>2</sup>. For patients with an eGFR  
270 <30 ml/min/1.73m<sup>2</sup>, the efficacy of SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor  
271 agonists, and insulin was evaluated. For patients receiving dialysis, the efficacy DPP-4  
272 inhibitors was compared with sulphonylureas but no other drugs were studied. None of the

273 RCTs evaluated the efficacy of glucose-lowering drugs in patients with a kidney transplant  
274 (Figures 4 and 5).

275

## 276 **Discussion**

277 In our systematic review, including almost 1200 RCTs and over 2.2 million patients, we have  
278 identified no improvement in the underrepresentation of patients with CKD over the past two  
279 decades. On the contrary, since 2000 the number of cardiovascular RCTs that excluded  
280 subgroups of patients with CKD has increased. Exclusion criteria were heterogenous and  
281 cardiovascular RCTs consistently excluded a larger number of patients with CKD than would  
282 be anticipated on safety grounds. In addition, only 13% of included cardiovascular RCTs  
283 evaluated the efficacy of CVRM medications for patients with CKD, mostly in subgroup  
284 analyses, resulting in evidence gaps across all CVRM medications and subgroups of patients  
285 with CKD.

286

287 The persistently high proportion of RCTs that exclude patients with CKD in the past 20 years  
288 cannot be attributed to a rise in the number of RCTs requiring dose-adjustment on kidney  
289 function for CVRM medications as the proportion of RCTs requiring such adjustment  
290 remained stable. While excluding patients with CKD from such RCTs due to safety concerns  
291 can be justifiable, the significantly more stringent kidney exclusion criteria compared to  
292 prescription thresholds in clinical practice suggest there are additional reasons for excluding  
293 patients with CKD. Practical issues like the necessity for dose adjustments, concerns about  
294 heterogeneity in treatment effects, or a limited life expectancy could also discourage clinical  
295 trialists from including patients with CKD in their RCTs.

296

297 The evidence gaps for patients with CKD in cardiovascular RCTs can be traced back to the  
298 ongoing widespread exclusion of this population. Excluding patients with CKD due to  
299 possible treatment heterogeneity or initial safety concerns does not necessarily lead to  
300 evidence gaps provided that separate RCTs are conducted to assess the efficacy of

301 medications for patients with CKD. However, in practice, only 0.25% of included  
302 cardiovascular RCTs was conducted specifically for patients with CKD.

303

304 *Implications for practice of the evidence gaps for CVRM medications in patients with CKD*

305 Currently, most RCTs which evaluated CVRM medications for patients with CKD focussed  
306 on those with CKD stage 3. For patients with CKD stage 4-5, which comprise 10% of the  
307 patients with CKD (i.e. 85 million patients) (41), analyses were often absent, particularly for  
308 those with a kidney transplant. The lack of RCTs assessing the efficacy of CVRM  
309 medications for patients with CKD means that, in practice, practitioners must resort to  
310 extrapolating results from RCTs conducted in other populations, assuming that the treatment  
311 effects are comparable. However, this assumption is increasingly less likely to hold for  
312 patients with more advanced CKD stages where CKD-specific risk factors like vascular  
313 calcification, uraemia, chronic inflammation, and immunosuppressive therapy to prevent graft  
314 rejection, combined with a very high risk and reduced life expectancy can modify the  
315 treatment effect (42, 43).

316

317 The complexity of extrapolating results to patients with CKD is illustrated by statins. Although  
318 these drugs reduce cardiovascular risk in patients with an eGFR  $<60$  ml/min/1.73m<sup>2</sup>, their  
319 efficacy has not been demonstrated in individuals with kidney failure (44). The lack of RCTs  
320 conducted in patients between these ends of the CKD spectrum makes it impossible to  
321 determine the tipping point where statins lose their benefits. Consequently, patients may  
322 unintentionally be over- or undertreated since the balance between benefits and side effects  
323 remains unknown.

324

325 In addition to an absolute lack of RCTs, limitations in the analyses further hamper CVRM  
326 treatment for patients with CKD. Heterogeneity in exclusion criteria and inadequate reporting  
327 of baseline kidney function reduce the comparability of RCTs while the small sample size of  
328 strata leads to underpowered analyses and imprecision in effect estimates. Furthermore, the

329 lack of RCTs evaluating the effect of CVRM medications on individual cardiovascular  
330 endpoints and kidney endpoints in patients with CKD means that the efficacy of these drugs  
331 on these individual endpoints remains unknown. More importantly, stratifying RCT cohorts  
332 breaks randomisation and can introduce confounding due to clustering of other CVD risk  
333 factors in patients with CKD (45, 46). These limitations are likely to amount in a GRADE  
334 recommendation of low or very low certainty of evidence for most CVRM medications in  
335 patients with CKD, meaning that their efficacy might be markedly different from the estimated  
336 effect (47).

337

### 338 *Implications for research*

339

340 An increasing prevalence of CKD (including dialysis and transplantation), the widespread  
341 prescription of CVRM medications to this population, and uncertainty about the efficacy of  
342 various CVRM medications in patients with CKD underscore the urgency of adequate  
343 representation of patients with CKD in cardiovascular RCTs (48, 49). Despite efforts of the  
344 United States Food and Drug Administration (FDA) and European Medicine Agency (EMA) to  
345 promote the enrolment of patients with CKD and numerous reviews and editorials addressing  
346 this issue, the representation of patients with CKD in cardiovascular RCTs has not improved  
347 in the past twenty years (12, 13, 50, 51). Bridging the evidence gap for treatment of  
348 cardiovascular risk in patients with CKD is the responsibility of different stakeholders  
349 including pharmaceutical companies, medicine regulatory authorities, scientific societies, and  
350 funding bodies and starts with the proportional inclusion of patients with CKD to enable  
351 (subgroup) analyses on kidney disease. New evidence for patients with CKD stage 4-5  
352 (including those receiving kidney replacement therapy) should be prioritized considering the  
353 evidence gaps are largest for this population. However, such analyses are only feasible if the  
354 enrolment of these patient improves and separate RCTs are conducted for them.  
355 Additionally, more evidence is needed on the efficacy of CVRM medications on individual  
356 cardiovascular and kidney endpoints. Innovative RCT designs like adaptive platform trials

357 based on a master protocol might be an attractive means to rapidly generate evidence for a  
358 range of treatment strategies for different groups of patients with CKD. Emulated target trials  
359 with real-world data present another opportunity to fill evidence gaps for the efficacy of  
360 CVRM medications in patients with CKD, especially for drugs regularly prescribed in practice  
361 where conducting new RCTs is prohibitively expensive and time consuming (52).

362

### 363 *Strengths and limitations*

364 The main strength of this review is its methodological rigour: we performed screening and  
365 data extraction in pairs and published our protocol a priori (17). Unlike previous reviews, we  
366 included all CVRM medications recommended in the major American and European  
367 guidelines and RCTs evaluating these medications both in primary and secondary prevention  
368 settings (18-39). Furthermore, this is the first study to compare the exclusion of patients with  
369 CKD with the recommended thresholds for dose-adjustment or contra-indications on kidney  
370 function. Limitations of this systematic review are that we might have underestimated the  
371 exclusion of patients with CKD in RCTs with ambiguous exclusion criteria such as chronic  
372 disease or life-limiting disease and have missed RCTs not registered in ClinicalTrials.gov.  
373 However, we are confident the number of missed RCTs is small since the sensitivity of  
374 searches in trial registries and electronic databases has demonstrated to be comparable  
375 (53). Moreover, our validation study showed that our search strategy identified almost all  
376 eligible RCTs from a bibliographic database search. Searching for RCTs registered in or after  
377 2000 may appear a limitation as we did not include most RCTs published before this date  
378 without retrospective registration. However, these older RCTs are less relevant for  
379 contemporary clinical practice and guidelines recommendations as more comprehensive  
380 CVRM care and new therapies have vastly improved patients' prognosis (54).

381

### 382 *Conclusion*



383 The representation of patients with CKD in cardiovascular RCTs has not improved in the past  
384 twenty years. Cardiovascular RCTs systematically excluded more patients with CKD than  
385 expected on safety grounds. The lack of cardiovascular RCTs that report results for patients  
386 with CKD has resulted in significant evidence gaps for the efficacy of most CVRM  
387 medications in patients with CKD, particularly for those with CKD stage 4-5.

388

#### 389 **Funding source**

390 This study was supported by the Dutch CardioVascular Alliance, an initiative with support of  
391 the Dutch Heart Foundation, 2020B008 RECONNECT. The sponsor had no role in the  
392 design, conduct and reporting of the study.

393

#### 394 **Other information:**

395 Registration and protocol

396

397 PROSPERO: CRD42022296746

398 Protocol: Colombijn JMT, Idema DL, van der Braak K, Spijker R, Meijvis SCA, Bots ML, et al.

399 Evidence for pharmacological interventions to reduce cardiovascular risk for patients with  
400 chronic kidney disease: a study protocol of an evidence map. *Syst Rev.* 2022;11(1):238.

401

#### 402 **Conflict of Interest Disclosures:**

403 The authors have no conflicts of interest to declare.

#### 404 **Availability of data, code, and other materials:**

405 All data in this review are based on publicly available articles. Dataset and syntax are  
406 available upon request

407

#### 408 **Bibliography:**

409 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and  
410 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of  
411 Disease Study 2017. *The Lancet.* 2020;395(10225):709-33.

- 412 2. Vaduganathan M, Mensah George A, Turco Justine V, Fuster V, Roth Gregory A. The Global  
413 Burden of Cardiovascular Diseases and Risk. *Journal of the American College of Cardiology*.  
414 2022;80(25):2361-71.
- 415 3. System USRD. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United  
416 States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney  
417 Diseases, Bethesda, MD, 2020.
- 418 4. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of  
419 Death in Patients with Reduced Kidney Function. *J Am Soc Nephrol*. 2015;26(10):2504-11.
- 420 5. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease:  
421 where does Europe go? *Clin J Am Soc Nephrol*. 2008;3(2):616-23.
- 422 6. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, et al. Relative incidence of  
423 ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from  
424 the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. *Am J*  
425 *Kidney Dis*. 2012;59(1):75-83.
- 426 7. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al.  
427 Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*.  
428 2013;382(9889):339-52.
- 429 8. Dahl H, Sandbløst SRT, Welland NL, Sandnes K, Sekse I, Sæle K, et al. Medication Prescription,  
430 Common Side-effects, and Nutritional Status are Associated in Patients With Chronic Kidney Disease.  
431 *Journal of Renal Nutrition*. 2022;32(5):520-8.
- 432 9. Becquemont L, Bauduceau B, Benattar-Zibi L, Berrut G, Bertin P, Bucher S, et al. Association  
433 between Cardiovascular Drugs and Chronic Kidney Disease in Non-Institutionalized Elderly Patients.  
434 *Basic & Clinical Pharmacology & Toxicology*. 2015;117(2):137-43.
- 435 10. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical  
436 trials in coronary artery disease. *Kidney Int*. 2006;70(11):2021-30.
- 437 11. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in  
438 randomized controlled trials of cardiovascular disease. *Jama*. 2006;296(11):1377-84.
- 439 12. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, et al. Representation of  
440 Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic  
441 Review. *JAMA Internal Medicine*. 2016;176(1):121-4.
- 442 13. Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent  
443 Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in  
444 the Contemporary Era. *J Am Soc Nephrol*. 2018;29(12):2782-6.
- 445 14. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic Kidney  
446 Disease and Coronary Artery Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*.  
447 2019;74(14):1823-38.
- 448 15. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney  
449 Disease: Pathophysiological Insights and Therapeutic Options. *Circulation*. 2021;143(11):1157-72.
- 450 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA  
451 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 452 17. Colombijn JMT, Idema DL, van der Braak K, Spijker R, Meijvis SCA, Bots ML, et al. Evidence for  
453 pharmacological interventions to reduce cardiovascular risk for patients with chronic kidney disease:  
454 a study protocol of an evidence map. *Syst Rev*. 2022;11(1):238.
- 455 18. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC  
456 Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the  
457 European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of  
458 extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by:  
459 the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral  
460 Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for  
461 Vascular Surgery (ESVS). *European Heart Journal*. 2018;39(9):763-816.

- 462 19. American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment:  
463 &lt;em&gt;Standards of Medical Care in Diabetes—2021&lt;/em&gt;. Diabetes Care.  
464 2021;44(Supplement 1):S111.
- 465 20. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019  
466 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American  
467 College of Cardiology. 2019;74(10):e177-e232.
- 468 21. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC  
469 Guidelines for the management of acute coronary syndromes in patients presenting without  
470 persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes  
471 in patients presenting without persistent ST-segment elevation of the European Society of Cardiology  
472 (ESC). European Heart Journal. 2021;42(14):1289-367.
- 473 22. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines  
474 on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The  
475 Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of  
476 Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart  
477 Journal. 2020;41(2):255-323.
- 478 23. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al.  
479 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery  
480 Disease: Executive Summary. Journal of the American College of Cardiology. 2017;69(11):1465-508.
- 481 24. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018  
482 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the  
483 Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-  
484 e350.
- 485 25. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC  
486 Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the  
487 European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and  
488 management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the  
489 special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart  
490 Journal. 2021;42(5):373-498.
- 491 26. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC  
492 Guidelines for the management of acute myocardial infarction in patients presenting with ST-  
493 segment elevation: The Task Force for the management of acute myocardial infarction in patients  
494 presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart  
495 Journal. 2018;39(2):119-77.
- 496 27. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS  
497 Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of  
498 Cardiology. 2014;64(21):e1-e76.
- 499 28. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al.  
500 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A  
501 Guideline From the American Heart Association/American Stroke Association. Stroke.  
502 2021;52(7):e364-e467.
- 503 29. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC  
504 Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the  
505 diagnosis and management of chronic coronary syndromes of the European Society of Cardiology  
506 (ESC). European Heart Journal. 2020;41(3):407-77.
- 507 30. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS  
508 Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk:  
509 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC)  
510 and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88.
- 511 31. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC  
512 Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task  
513 Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of

- 514 Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.  
515 European Heart Journal. 2021;42(36):3599-726.
- 516 32. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018  
517 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165.
- 518 33. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA  
519 Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American  
520 College of Cardiology. 2021;77(4):e25-e197.
- 521 34. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European  
522 Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the  
523 European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical  
524 Practice (constituted by representatives of 10 societies and by invited experts)Developed with the  
525 special contribution of the European Association for Cardiovascular Prevention & Rehabilitation  
526 (EACPR). European Heart Journal. 2016;37(29):2315-81.
- 527 35. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International  
528 Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57.
- 529 36. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS  
530 Guidelines for the management of valvular heart disease: Developed by the Task Force for the  
531 management of valvular heart disease of the European Society of Cardiology (ESC) and the European  
532 Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021:ehab395.
- 533 37. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC  
534 Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-  
535 337.
- 536 38. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017  
537 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,  
538 Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American  
539 College of Cardiology. 2018;71(19):e127-e248.
- 540 39. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH  
541 Guidelines for the management of arterial hypertension: The Task Force for the management of  
542 arterial hypertension of the European Society of Cardiology (ESC) and the European Society of  
543 Hypertension (ESH). European Heart Journal. 2018;39(33):3021-104.
- 544 40. Ashley C, Dunleavy A. The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal  
545 Practitioners. 5th Edition ed: CRC press; 2018.
- 546 41. Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence,  
547 outcomes, and cost of chronic kidney disease in a contemporary population of 2&#x7;4 million  
548 patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health – Europe. 2022;20.
- 549 42. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome:  
550 Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the  
551 American Heart Association. Circulation. 2019;139(16):e840-e78.
- 552 43. Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, et al. Cardiovascular  
553 outcome trials in patients with chronic kidney disease: challenges associated with selection of  
554 patients and endpoints. Eur Heart J. 2019;40(11):880-6.
- 555 44. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM:  
556 An International Journal of Medicine. 2017;110(8):493-500.
- 557 45. VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials:  
558 heterogeneity versus secondary interventions. Ann Intern Med. 2011;154(10):680-3.
- 559 46. Groenwold RH, Donders AR, van der Heijden GJ, Hoes AW, Rovers MM. Confounding of  
560 subgroup analyses in randomized data. Arch Intern Med. 2009;169(16):1532-4.
- 561 47. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.  
562 Introduction&#x2014;GRADE evidence profiles and summary of findings tables. Journal of Clinical  
563 Epidemiology. 2011;64(4):383-94.
- 564 48. Wang JH, Hart A. Global Perspective on Kidney Transplantation: United States. Kidney360.  
565 2021;2(11).

- 566 49. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global Epidemiology of  
567 End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. *American Journal of*  
568 *Nephrology*. 2021;52(2):98-107.
- 569 50. Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with  
570 Impaired Renal Function – Study Design, Data Analysis, and Impact on Dosing. 2020.
- 571 51. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of  
572 medicinal products in patients with decreased renal function. 2015 16 March 2023.
- 573 52. Sendor R, Stürmer T. Core concepts in pharmacoepidemiology: Confounding by indication  
574 and the role of active comparators. *Pharmacoepidemiol Drug Saf*. 2022;31(3):261-9.
- 575 53. Knelangen M, Hausner E, Metzendorf MI, Sturtz S, Waffenschmidt S. Trial registry searches  
576 for randomized controlled trials of new drugs required registry-specific adaptation to achieve  
577 adequate sensitivity. *J Clin Epidemiol*. 2018;94:69-75.
- 578 54. ClinicalTrials.gov. 2021 [Available from: <https://clinicaltrials.gov/ct2/manage-recs/fdaaa>.  
579

580

581  
582  
583

**Tables**

Table 1: characteristics of included RCTs

Variables	All (n=1194)	Exclusion of people with CKD (n=884)	No exclusion of people with CKD (n=310)
<b>Study characteristics</b>			
Year of publication			
<2000	21(2)	12 (1)	9 (3)
2000-2005	50 (4)	33 (4)	17 (5)
2006-2010	239 (20)	173 (20)	66 (21)
2011-2015	393 (33)	286 (32)	107 (34)
2016-2020	418 (35)	322 (36)	96 (31)
>2020	73 (6)	58 (7)	15 (5)
Sample size			
Total	2207677	1.595.831	563.038
Median [IQR]	568 [304 – 1315]	559 [311 – 1250]	530 [280 – 1288]
Follow-up (months)	24.0 [12.0 – 39.6]	26.4 [12.0 – 40.8]	17.8 [5.5 – 30.0]
Only protocol published	81 (7)	64 (8)	17 (5)
Location			
Multi-continental	576 (48)	443 (50)	133 (43)
Europe	165 (14)	117 (13)	48 (16)
North America	172 (14)	116 (13)	53 (17)
Asia/Australia/Africa/Other	281 (24)	208 (24)	73 (24)
Funding source <sup>#</sup>			
Industry	987 (83)	736 (83)	251 (81)
Government	81 (7)	57 (8)	24 (6)
Institutional	151 (13)	110 (12)	41 (13)
Unspecified/miscellaneous	49 (4)	35 (4)	14 (5)
Type of intervention			
Antihypertensives	221 (19)	182 (20)	39 (13)
Glucose lowering drugs	552 (46)	424 (48)	128 (41)
Lipid lowering drugs	162 (14)	126 (15)	36 (12)
Antiplatelets or anticoagulants	229 (19)	132 (15)	97 (31)
Combination of interventions	30 (3)	20 (2)	10 (3)
<b>Participant characteristics</b>			
Age (years)	63 ± 6	64 ± 6	62 ± 6
Sex (% female)	36 ± 12	37 ± 12	33 ± 12
eGFR (ml/min/1.73m <sup>2</sup> )*			
mean (SD)	73 ± 13	73 ± 13	77 ± 10
Not reported	899 (75)	623 (71)	276 (89)
≥90,	79 (27)	74 (28)	5 (14)
60-89	169 (57)	144 (55)	25 (73)
45-59	27 (9)	24 (9)	3 (8)
30-44	13 (4)	13 (5)	0 (0)
15-29	7 (2)	6 (3)	1 (3)
Serum creatinine (mg/dL)*			
Median [IQR]	1.00 [0.96 – 1.04]	1.00 [0.97 – 1.04]	1.00 [0.95 – 1.01]
Not reported	1040 (87)	750 (85)	290 (94)
<1.0	77 (50)	67 (50)	10 (50)
1.0-1.49	61 (40)	51 (38)	10 (50)
1.5-2.00	9 (6)	9 (7)	0 (0)
>2.0	7 (5)	7 (5)	0 (0)
Dialysis	17 (<1)	17 (2)	0 (0)
Transplantation	1 (<1)	1 (<1)	0 (0)

584 Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range.  
585 Categorical variables are describes as n (percentage). Normally distributed continuous variables as mean ± SD  
586 and skewedly distributed variables as median [IQR].

587 # RCTs can have multiple funding sources. Therefore percentages do not add up to 100 percent.

588 \*percentages only for proportion without missing eGFR or serum creatinine.

589  
590  
591



## 592 **Figures**

593 **Figure 1:** Overview of the exclusion of people with CKD from cardiovascular RCTs. Panel A shows the  
594 percentage of RCTs that exclude (subgroups of) people with different stages of CKD over time; panel B shows  
595 the exclusion of people with CKD for different types of CVRM medications; panel C shows the most commonly  
596 used exclusion criteria for eGFR (ml/min/1.73m<sup>2</sup>), serum creatinine (mg/dL), and other kidney exclusion criteria,  
597 respectively.

598

599 Abbreviations:

600 ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel  
601 blocker; CKD, chronic kidney disease; DOAC, direct oral anticoagulants; DPP-4 receptor agonist, dipeptidyl-  
602 peptidase-4 inhibitors; eGFR, estimated glomerular filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1  
603 receptor agonist; MRA, mineralocorticoid receptor antagonist; PSCK-9 inhibitor, proprotein convertase  
604 subtilisin/kexin type 9 inhibitor; SCr, serum creatinine; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor.

605

606 Other eGFR exclusion criteria were eGFR <40 (n=8); <25 (n=7); >60 and <30, <35 (both n=5); eGFR >50, >60  
607 (both n=3); eGFR <36, >30, >70 and <20, >60 and <15, >60 and <45, creatinine clearance <60% of the normal  
608 age-adjusted value (all n=2); eGFR <10, >45 and <20, >45 and <25, >50 and <30, >60 and <25, >75 and, <25,  
609 >80 and <20, >90 and <25, >90 and <30, <70, <90, not satisfying eGFR (all n=1). Other serum creatinine  
610 exclusion criteria were serum creatinine >1.3 (M) >1.2 (F) (n=7); serum creatinine >1.5 (M) >1.2 (F) (n=6); serum  
611 creatinine >1.5 (M) >1.3 (F) (n=5); serum creatinine >1.4, >2.3, elevated serum creatinine level (all n=4); serum  
612 creatinine >4, (not further specified; n=3); serum creatinine >1.5 times ULN (M), > 1.4 times ULN (F); >1.5times  
613 ULN, >2 times ULN, >3 times ULN, >1.6, >1.8, >2 (M) >1.8 (F), >3 and <1.5 (M), >3 and <1.3 (F) (all n=2); <1.7  
614 (M) <1.5 (F); serum creatinine <2, >2.5 and <1.2 (M), <1.0 (F), >5, and <1.5, >1.7 (M) >1.5 (F), >1.5 (M) >1.1 (F),  
615 >1.6 (M) >1.5 (F), >2 (M) >1.5 (F), >2 (M) >1.7 (F), >2.2, >2.4, >2.4 (M) > 2.0 (F), >2.7, >3.5, >6 (all n=1). Other  
616 kidney exclusion criteria were not receiving dialysis (n=8); abnormal laboratory results on kidney function tests  
617 (not further specified; n=4); serum creatinine or creatinine clearance that was a contraindication to metformin  
618 according to the country-specific label (n=2); expected Kidney transplant within 1 year and not on dialysis,  
619 patients with serious kidney damage, renal artery stenosis in a solitary kidney or kidney transplant or, one  
620 functioning kidney, no kidney transplant, polycystic kidney disease, unsuccessful kidney transplantation (all n=1).

621

622 **Figure 2:** Exclusion of patients with CKD stratified by prescription recommendations for patients with CKD. Panel  
623 A shows the percentage of RCTs that exclude different subgroups of patients with CKD stratified by  
624 recommendations for dose-adjustment or contra-indications; panel B shows the percentage of RCTs over time  
625 where dose adjustment is recommended.

626 Abbreviations: CKD, chronic kidney disease

627

628 **Figure 3:** Number of RCTs with analyses for people with CKD for different types of CVRM medications. panel A  
629 shows the number of analyses for people with CKD for different cardiovascular endpoints; Panel B shows the  
630 percentage of RCTs with analyses for people with any CKD and CKD stage 4-5.

631

632 Abbreviations:

633 CAD, coronary artery disease; CeVD, cerebrovascular disease; CKD, chronic kidney disease; MACE, major  
634 adverse cardiovascular event; PAD, peripheral arterial disease.

635

636 **Figure 4:** Heat map of (subgroup) analyses for major adverse cardiovascular events for people with different  
637 stages of CKD.

638 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
639 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
640 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
641 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
642 antagonist; PCSK-9 inhibitor, proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
643 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
644 vitamin K antagonist.

645

646 **Figure 5:** Overview of individual studies with analysis on eGFR or kidney replacement therapy for major adverse  
647 cardiovascular events in patients with CKD. Panel A illustrates analyses for antithrombotics; panel B for blood-  
648 pressure-lowering drugs; panel C for cholesterol-lowering drugs; panel D for glucose-lowering drugs; and panel E  
649 for polypills.

650

651 Abbreviations:

652 ACE-inhibitor/ACE-I, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAA, centrally-acting  
653 antihypertensive; CCB, calcium channel blocker; CKD, chronic kidney disease; DAPT, double antiplatelet therapy;  
654 DOAC, direct oral anticoagulants; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitor; eGFR, estimated glomerular  
655 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; KRT, kidney replacement  
656 therapy; MRA, mineralocorticoid receptor antagonist; PCSK-9 inhibitor, proprotein convertase subtilisin/kexin type  
657 9 inhibitor; SAPT, single antiplatelet therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT,  
658 triple antiplatelet therapy; VKA, vitamin K antagonist.

659



## 660 **Supplementary Figures**

661 **Supplementary Figure 1:** Flow chart of literature search.

662 **Supplementary Figure 2:** Exclusion of patients with CKD stratified by prescription recommendations for patients  
663 with CKD.

664 **Supplementary Figure 3:** Heat map of (subgroup) analyses for all-cause mortality for people with different  
665 stages of CKD.

666 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
667 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
668 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
669 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
670 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
671 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
672 vitamin K antagonist.

673

674 **Supplementary Figure 4:** Heat map of (subgroup) analyses for cardiovascular mortality for people with different  
675 stages of CKD.

676 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
677 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
678 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
679 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
680 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
681 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
682 vitamin K antagonist.

683

684 **Supplementary Figure 5:** Heat map of (subgroup) analyses for coronary artery disease for people with different  
685 stages of CKD.

686 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
687 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
688 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
689 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
690 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
691 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
692 vitamin K antagonist.

693

694 **Supplementary Figure 6:** Heat map of (subgroup) analyses for heart failure for people with different stages of  
695 CKD.

696 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
697 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
698 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
699 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
700 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
701 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
702 vitamin K antagonist.

703

704 **Supplementary Figure 7:** Heat map of (subgroup) analyses for cerebrovascular disease for people with different  
705 stages of CKD.

706 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
707 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
708 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
709 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
710 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
711 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
712 vitamin K antagonist.

713

714 **Supplementary Figure 8:** Heat map of (subgroup) analyses for peripheral arterial disease for people with  
715 different stages of CKD.

716 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
717 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;  
718 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
719 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
720 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
721 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
722 vitamin K antagonist.


723

724 **Supplementary Figure 9:** Heat map of (subgroup) analyses kidney failure for people with different stages of  
725 CKD.


726 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,  
727 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;

728 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular  
729 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor  
730 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet  
731 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,  
732 vitamin K antagonist.


A





B




C








A




B













C



D



E

